"Claudins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large family of transmembrane proteins found in TIGHT JUNCTIONS. They take part in the formation of paracellular barriers and pores that regulate paracellular permeability.
| Descriptor ID |
D057167
|
| MeSH Number(s) |
D12.776.543.940.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Claudins".
Below are MeSH descriptors whose meaning is more specific than "Claudins".
This graph shows the total number of publications written about "Claudins" by people in this website by year, and whether "Claudins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 4 | 4 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Claudins" by people in Profiles.
-
Vascular heterogeneity of tight junction Claudins guides organotropic metastasis. Nat Cancer. 2024 Sep; 5(9):1371-1389.
-
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024 Aug; 9(8):103663.
-
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024 Sep; 27(5):1058-1068.
-
The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer. Expert Opin Drug Discov. 2024 Aug; 19(8):873-886.
-
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncol. 2024; 20(26):1861-1877.
-
Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma. JCO Precis Oncol. 2024 May; 8:e2300543.
-
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies. Curr Opin Oncol. 2024 Jul 01; 36(4):308-312.
-
Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma. Curr Oncol. 2024 02 01; 31(2):769-777.
-
MRCK as a Potential Target for Claudin-Low Subtype of Breast Cancer. Int J Biol Sci. 2024; 20(1):1-14.
-
Argininosuccinate lyase deficiency causes blood-brain barrier disruption via nitric oxide-mediated dysregulation of claudin expression. JCI Insight. 2023 09 08; 8(17).